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Abstract Management of portal hypertension in children
has evolved over the past several decades. Portal hyperten-
sion can result from intrahepatic or extrahepatic causes.
Management should be tailored to the child based on the
etiology of the portal hypertension and on the functionality
of the liver. The most serious complication of portal
hypertension is gastroesophageal variceal bleeding, which
has a mortality of up to 30%. Initial treatment of bleeding
focuses on stabilizing the patient. Further treatment meas-
ures may include endoscopic, medical, or surgical inter-
ventions as appropriate for the child, depending on the
cause of the portal hypertension. β-Blockers have not
been proven to effectively prevent primary or secondary
variceal bleeding in children. Sclerotherapy and variceal
band ligation can be used to stop active bleeding and can
prevent bleeding from occurring. Transjugular intrahe-
patic portosystemic shunts and surgical shunts may be
reserved for those who are not candidates for transplant
or have refractory bleeding despite medical or endoscopic
treatment.
Keywords Portal hypertension . Pediatric . Variceal
hemorrhage . Variceal ligation . Sclerotherapy . Balloon
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Introduction
Portal hypertension is defined as portal vein pressures
exceeding 5 mm Hg or portal vein to hepatic vein gradient
of greater than 10 mm Hg; variceal bleeding is associated
with a gradient above 12 mm Hg [1, 2]. When the portal
system becomes congested, collateral pathways develop at
the junctions between the high-pressure portal vessels and
the low-pressure venous system, thereby forming varices.
Variceal formations occur predominantly in the esophagus
and in the stomach, retroperitoneally, and around the rectum
and umbilicus (caput medusa). The most serious complication
of portal hypertension is variceal bleeding, usually in the
esophagus or stomach. Variceal hemorrhage is associated with
a significant mortality rate of up to 30% [3]. Understanding
the pathophysiology of portal hypertension is crucial to its
diagnosis and management. Portal hypertension is caused by
disruption of flow through the portal system and can be
categorized into intrahepatic and extrahepatic etiologies.
Extrahepatic causes can be further classified by prehepatic
and posthepatic sites. Intrahepatic etiologies include presi-
nusoidal, sinusoidal, or post-sinusoidal obstruction. Current-
ly, portal hypertension in children most commonly results
from an intrahepatic etiology, cirrhosis, or sinusoidal
obstruction, which can occur with a multitude of liver
diseases but predominantly with biliary atresia. Extrahepatic
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causes include obstruction of the portal vein, typically from
instrumentation of the umbilical vein (usually during the
neonatal period). Other etiologies include infection (eg.
omphalitis), intra-abdominal abscess, severe dehydration,
and blunt trauma to the abdomen. Additionally, Budd-
Chiari syndrome, veno-occlusive disease, and cardiac disease
can cause portal hypertension.
The natural history of variceal formation and bleeding in
the presence of cirrhosis can occur fairly rapidly in
children. A recent study of 139 children with biliary atresia
found that 125 (90%) showed signs of portal hypertension
and underwent endoscopy at a median age of 13 months.
Of those 125 children, 88 (70%) had variceal formation.
Gastrointestinal bleeding occurred in 20% of the 139
subjects at a median age of 17 months for the first bleed,
with 75% of them bleeding prior to 2.5 years [4•].
Diagnosis and Evaluation
Portal hypertension is identified by a thorough history and
physical examination. The history should focus on identi-
fying factors that predispose the child to developing portal
hypertension, such as family history of metabolic liver
disease, personal history of hypercoagulable state, or
history of umbilical vein instrumentation or abdominal
infection. On examination, the majority of children with
portal hypertension will have an enlarged spleen, unless
other anomalies are present, such as asplenia or polysplenia
(which can be seen in biliary atresia). Occasionally, ascites
is present if the cause of portal hypertension is intrahepatic.
The liver may be enlarged, but often is small and shrunken,
and thus is an unreliable physical examination finding.
Portal congestion can be seen rarely on physical examina-
tion as external or internal hemorrhoids and caput medusa.
Imaging studies can also help confirm the presence of
portal hypertension, including ultrasound with Doppler,
contrast-enhanced CT, and magnetic resonance angiogra-
phy [5•]. Ultrasound can demonstrate heterogeneity of the
liver in chronic liver disease, and Doppler examination
provides information about portal vein patency and direc-
tionality of flow, both of which are important in the
diagnosis and management of portal hypertension [5•].
Esophagogastroduodenoscopy (EGD) is the best mode
to screen for esophageal and gastric varices and should be
done once portal hypertension is suspected. However, a
recent study by McKiernan et al. [6] showed that
endoscopic ultrasound (EUS) was superior to visual
examination by EGD in detecting early gastroesophageal
varices in children with intestinal failure–associated liver
disease. The study investigators evaluated 16 children,
using upper endoscopy and EUS. Seven subjects were
found to have gastroesophageal varices by EUS, although
the varices were not seen on visual examination, indicating
that EUS helps detect varices at an earlier stage than EGD
[6]. Nevertheless, EGD has been important in detecting
features associated with increased likelihood of bleeding,
such as large tense varices, red spots, and red wale
markings, information that is crucial for initiating treatment
of an identified bleeding site [7, 8]. Additionally, the
variceal grade identified and the presence of gastric varices
were shown to be predictive of the risk of gastrointestinal
bleed. The 5-year risk of bleeding from biliary atresia
patients is 59% with grade 3 varices, 17% with grade 2
varices, and 12% with no varices visible on initial
endoscopy [4•].
Management of an Acute Variceal Bleed
Acute gastrointestinal hemorrhage from variceal rupture in
the esophagus or stomach often is a medical emergency,
with 6-week mortality rates approaching 30% in those with
severe liver disease [3]. Children may have large-volume
hematemesis or melena and may present in cardiovascular
shock. Stabilizing the patient is the initial focus of
management of gastrointestinal hemorrhage. Two large-
bore intravenous (IV) catheters must be placed immediately
so that volume replacement with fluids and packed red
blood cells can be delivered rapidly. When large-bore IV
catheters cannot be established in children, intraosseous
needles must be placed. Patients with coagulopathy from
hepatic dysfunction and thrombocytopenia may require
administration of IV vitamin K, fresh frozen plasma,
cryoprecipitate, factor VIIa, and/or platelets to help stop
the bleeding. Nasogastric tube placement and gastric lavage
are helpful in confirming that the site of bleeding is in the
upper gastrointestinal tract. Additionally, they provide
information about the extent of bleeding. Gastric lavage is
usually done with room-temperature saline or sterile water
and helps to evacuate the blood from the stomach, which
allows for better visualization of the mucosa at the time of
endoscopy. Initiation of an IV histamine2 receptor blocker
or proton pump inhibitor helps to decrease the risk of
bleeding from erosions or ulcerations. Once the child has
been resuscitated, upper endoscopy should be performed to
assess for the site of bleeding and initiate treatment, if
indicated. Endoscopic treatment may include sclerotherapy,
variceal banding, or injection of cyanoacrylate glue for
gastric varices. Endoscopic treatments are discussed in
detail below.
If bleeding cannot be controlled with the above
measures, balloon tamponade with a Linton tube, Minne-
sota tube, or Sengstaken-Blakemore tube can be attempted.
The Linton tube is a single-balloon tube used to stop the
bleeding from gastric varices; the Minnesota and
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Sengstaken-Blakemore tubes have two balloons, one for the
stomach for gastric varices, and the other for esophageal
varices. The length of the esophageal balloon limits the use
of the Minnesota and Sengstaken-Blakemore tubes to
children weighing more than 40 kg. Bleeding can be
stopped in almost 90% of cases by balloon tamponade;
however, the tubes are only temporizing measures and
cannot be kept in place for more than 24 h [9]. Tube
placement should be attempted only by individuals who
have been trained and are comfortable with their use,
because complication rates are high when the tubes are not
properly placed. Complications include esophageal perfo-
ration, aspiration, mucosal ischemia, and airway obstruction
[9, 10]. When balloon tamponade is required, there should
be a low threshold for intubation, and intubation is highly
recommended.
Pharmacologic Treatment
The goal of pharmacologic intervention is to decrease
portal pressure. The medications are classified into those
that 1) stop active variceal bleeding, and 2) prevent variceal
formation and variceal bleeding.
Vasoactive Medications
Vasoactive medications such as vasopressin, somatostatin,
and octreotide are used to control active variceal bleeding.
Vasopressin, the prototype drug in this group, increases
splanchnic vascular tone and, as a result, decreases arterial
splanchnic flow and decreases portal venous pressure. It is
used as a continuous infusion of 0.002 to 0.005 U/kg/minute,
to a maximum dose of 0.01 U/kg/minute. Although vasopres-
sin was shown to control variceal hemorrhage in 53% of
children, significant side effects are associated with
vasoconstriction of the systemic blood pressure—causing
ischemia to the bowel, heart, and kidneys—that make it
undesirable for use [11]. Nitroglycerin has been used as a
potent vasodilator to counter these effects, but this
combination is not the most ideal for treatment of active
variceal bleeding.
Somatostatin is a naturally occurring 14-amino acid
peptide, and octreotide is an 8-amino acid synthetic
analogue of somatostatin. Octreotide and somatostatin have
the same pharmacologic effects, but octreotide has a longer
half-life and therefore is used more often in the clinical
setting [12]. Both medications decrease splanchnic blood
flow and azygous blood flow and have less systemic
vasoconstriction than vasopressin. The utility of octreotide
or somatostatin in controlling variceal bleeding has been
well studied in adults, but few studies have been performed
in children. In 2001, Lam et al. [13] reported on the use of
octreotide in variceal bleeding in three children. Another
study reported on seven children with upper gastrointestinal
bleeding (five from variceal bleeds) and found that bleeding
stopped in six of the seven subjects who were given
octreotide [14]. The largest retrospective series was
described in 2004 by Eroglu et al. [15], who found that
octreotide stopped gastrointestinal bleeding from portal
hypertension in 71% of children. This cohort demonstrated
a 52% post-treatment re-bleeding rate and mortality of
19%. Octreotide dosing recommendations include a bolus
of 1 to 2 μg/kg followed by a 1 to 2 μg/kg/hour infusion.
The continuous infusion is titrated to effect. Once hemo-
stasis is obtained, the dosing is tapered by 50% every 12 h
for 24 h, and then stopped [16]. Octreotide can be used to
help stop or control an active bleed prior to endoscopy or
when endoscopy cannot be performed.
β-Blockers
β-Blockers have no role in controlling acute gastrointesti-
nal bleeding; however, they have been used in an attempt to
prevent variceal formation and bleeding. Their role as a
preventative has been well studied in adults. However, their
use in children has been empirical and is based on case
reports; no controlled or large studies have been done in
children to support the effectiveness of β-blockers in
preventing primary or secondary variceal bleeding.
Nonselective β-blockers have been used to reduce portal
pressure and prevent primary and secondary bleeding
episodes. They reduce portal hypertension by decreasing
cardiac output and inducing splanchnic vasoconstriction
through blockade of the β-1 and β-2 receptors [17]. In
adult studies, β-blockers were shown to reduce the risk of
variceal bleeding by about 50% [18]. In children, however,
the benefits of β-blockade in reduction of primary or
secondary bleeding are not clearly defined. The initial study
of propranolol in children was published in 1985 [19].
Thirteen children with portal hypertension were given
between 2 and 8 mg/kg/day of propranolol, with resultant
decrease in heart rate of about 25% of baseline. Portal
pressures as assessed by splenic pulp pressure were found
to have been decreased by about 13% in children with
compensated cirrhosis. No effect was seen in children with
decompensated portal hypertension [19]. Regardless of the
13% decrease in those with compensated cirrhosis, the
measurement of splenic pulp pressure has not been
validated as a good predictive tool of portal hypertension.
Another report of β-blocker use for children with portal
hypertension was a case series of 21 patients. Of the 21
children, 19 had cirrhosis and two had extrahepatic portal
vein obstruction. Propranolol dosing was adjusted to
achieve a 25% reduction in baseline heart rate. Thirty-
three percent had a gastrointestinal hemorrhage during the
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follow-up period, median time of hemorrhage occurred at
3 years [20]. An additional study showed similar results,
with bleeding rates of 15.6% in children taking propranolol
for primary prophylaxis of variceal bleeding, and bleeding
rates of 53% in those using the β-blocker for secondary
prophylaxis [21]. These results show that even on propran-
olol, bleeding rates occurred at 15.6% to 33%, which is not
significantly improved from baseline bleeding rates seen in
the natural history of this disease. Further, the use of β-
blockers has a theoretical risk of harm from the β-1
receptor blockade causing decreased cardiac output, which
may hinder appropriate heart rate increases during severe
hemorrhage. At this point, β-blockers should not be
routinely used in children as primary or secondary
prophylaxis of variceal bleeding. Randomized, controlled
trials are needed to evaluate the effects of nonselective β-
blockers in children.
Sclerotherapy and Variceal Ligation
Sclerotherapy and variceal ligation provide an alternative
option for treatment of actively bleeding varices and to help
prevent variceal bleeding. Since the late 1980s, various
studies have examined the use of sclerotherapy in children
for extrahepatic and intrahepatic etiologies of portal
hypertension, primarily as a means of stopping active
bleeding and to obliterate varices entirely by using multiple
treatments [22–31, 32•, 33–35]. The initial paper in 1988
by Howard et al. [22] retrospectively evaluated the out-
comes of 108 children with variceal bleeding managed by
injection sclerotherapy. Variceal obliteration was successful
in 92% of those with extrahepatic portal hypertension and
in 75% of those with intrahepatic portal hypertension. An
additional 11 subjects with no prior history of bleeding
were included, and sclerotherapy was used as a prophylac-
tic technique in these children [22]. The other studies
showed similar results; bleeding was stopped in about 92%
to 95% of subjects, regardless of whether the bleeding had
intrahepatic or extrahepatic etiologies. Additionally, scle-
rotherapy was shown to be useful even in very small
children as young as 5 months and weighing only 5.5 kg
[32•].
Despite the number of studies evaluating the role of
sclerotherapy, only one randomized, controlled trial in
children has looked at the value of endoscopic sclerother-
apy on prevention of esophageal variceal hemorrhage. The
study was performed in Brazil; 50 children in the
sclerotherapy group received treatment every 21 days until
the varices were obliterated, and 50 children in the control
group received regular clinical and endoscopic examina-
tions. After treatment was completed with sclerotherapy
(mean 3.5±2.6 sessions), patients were followed for
18 months with endoscopic evaluations done every
6 months. The sclerotherapy group had only 6% esophageal
variceal bleeding and 24% upper gastrointestinal bleeding
during the trial, whereas the control group had 42% variceal
bleeding and 48% upper gastrointestinal bleeding. Howev-
er, mortality rates in both groups were the same, and the
number of subjects with congestive hypertensive gastro-
pathy increased in the treatment group [34].
Although endoscopic sclerotherapy has been used
widely with effective treatment of bleeding, side effects
from the sclerosant can be significant, such as perforation,
bleeding, ulceration, and stricture formation at the injection
site. Endoscopic variceal ligation (EVL) was subsequently
developed and used in adults as an alternative treatment for
esophageal varices, and was found to be superior to
sclerotherapy in subjects with cirrhosis [35]. A randomized,
controlled trial was published in 2002 evaluating the
efficacy and safety of endoscopic sclerotherapy compared
with endoscopic ligation in children. This study compared
the two methods in 49 children with extrahepatic portal
venous obstruction who had a history of bleeding varices.
The EVL group included 25 subjects and the sclerotherapy
group had 24 subjects. Variceal eradication was similar in
the EVL group (96%) and the sclerotherapy group (92%).
Variceal ligation, however, was able to eradicate the varices
in fewer sessions than the sclerotherapy group (3.9±1.1 vs
6.1±1.7, respectively, P<0.0001). Re-bleeding rates prior
to variceal eradication were higher in the sclerotherapy
group than in the EVL group (25% vs 4%, P=0.049).
Subjects in both groups were followed for about 22 months
after variceal eradication. Recurrence rates of esophageal
varices were not significantly different in the two groups
(10% in sclerotherapy group vs 17.4% in the EVL group)
[36]. Another study investigated using EVL as a prophy-
lactic measure to prevent first-time bleeding in children and
adolescents with portal hypertension. Thirty-one children
(aged 4 to 17 years) completed the study; 16 had portal
hypertension from intrahepatic causes and 15 had portal
hypertension from portal vein thrombosis. Of the 31
children, eradication of varices was achieved in 28
(90.3%). No esophageal variceal bleeding occurred after
or between treatments, and obliteration of the varices
occurred on average after two to three treatments done at
3-month intervals. Two children developed hypertensive
gastropathy, and one of them bled from this. Three children
had recurrence of varices: one child with extrahepatic portal
hypertension had varices recur at 13 months; the other two
children, with intrahepatic portal hypertension, developed
recurrent varices at 12 and 28 months [37].
Another therapeutic option very recently investigated in
children is the use of cyanoacrylate glue for gastric varices
[38]. This technique has been successfully used in adults
for control of gastric varices [38, 39]. A pilot study looked
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at the use of N-butyl-2-cyanoacrylate (Glubran 2; GEM Srl,
Viareggio, Italy) in children younger than 2 years old and
weighing less than 10 kg who had gastroesophageal
varices. Seven of the 8 patients in the pilot study had
active bleeding, and one patient had bled within 3 weeks
prior to use of cyanoacrylate. Glue injection was successful
in all infants, with 0.5 to 2 mL injected. Immediate control
of bleeding was achieved in those with active bleeding. Re-
bleeding from gastric varices occurred in three of the eight
patients (37.5%), requiring a second treatment with cyano-
acrylate. The use of cyanoacrylate glue clearly needs
further investigation in infants and children, but thus far
the results are promising for ability to stop active gastric
variceal bleeding.
Despite the results of the above studies, esophageal
variceal ligation cannot be performed in all children
because of the size of the child’s esophagus compared to
the scope size and the associated ligature attachment, which
can significantly obscure the view from the scope. The
youngest child in studies where EVL was performed was
4 years old, but even infants as young as 5 months may
require endoscopy and intervention for variceal formation
and bleeding; in such circumstances, sclerotherapy can be
crucial for treatment.
Surgical Management and Transjugular Intrahepatic
Portosystemic Shunts
Esophageal variceal ligation, sclerotherapy, and medical
treatments are useful in controlling variceal bleeding;
however, these therapeutic measures do not treat the
underlying cause. Transjugular intrahepatic portosystemic
shunts (TIPS) and surgical shunts are the only means of
helping to reduce portal pressure and in some cases
definitively treat the underlying cause of portal hyperten-
sion. Candidates for TIPS or surgical shunts include
children with extrahepatic portal vein obstruction, those
with well-compensated cirrhosis who are unlikely to
receive a transplant soon, and those with persistent variceal
bleeding despite other management.
Transjugular intrahepatic portosystemic shunt (TIPS) is
an interventional radiographic technique that places an
intrahepatic metallic stent between the intrahepatic portions
of the portal vein and the hepatic vein, thus creating a
nonselective portocaval shunt. Because the shunt is nonse-
lective, hepatic encephalopathy can occur. Other potential
complications include shunt stenosis/thrombosis, bleeding,
portal vein thrombosis, and migration of the stent into the
right atrium. As with the other treatment modalities, it has
been successfully used and studied in adults, but reports in
children remain limited to case reports [40]. The limitations
are generally related to the fact that many children with
portal hypertension have cirrhosis because of biliary atresia
and often have abnormal portal vein anatomy; moreover,
the size of the child can lead to hepatic perforation and stent
malposition. Despite the limitations and risks, TIPS is
useful in variceal bleeding that is refractory to medical and
endoscopic management, and can be a bridge to getting the
patient to transplant. A recent study in adults by Garcia-
Pagan et al. [41•] looked at use of TIPS in patients with
cirrhosis and acute variceal bleeding, and randomly assigned
them to early TIPS placement (within 72 h of hospitaliza-
tion) or to medical treatment and EVL. In this particular
patient population with a high risk for treatment failure
(Child-Pugh class B with persistent bleeding or Child-Pugh
class C), those who were placed in the early TIPS
intervention group had improved mortality rates (12% vs
38%) and a reduction in treatment failure [41•].
Children with extrahepatic portal vein obstruction are
particularly good candidates for surgical shunts. The shunts
are divided into two groups: nonselective and selective
shunts. The nonselective shunts, such as the mesocaval
shunt and portocaval shunts, communicate with the entire
portal system and have been associated with higher rates of
hepatic encephalopathy compared with the selective shunts.
One of the most common selective shunts is the distal
splenorenal shunt (DSRS, Warren shunt). The DSRS,
unlike the nonselective shunts, provides a way to decom-
press gastroesophageal varices via the short gastric veins
and splenic vein while preserving the antegrade perfusion
to the liver, which makes hepatic encephalopathy less
likely. DSRS has been used successfully to improve severe
thrombocytopenia and leukopenia [42]. The mesenteric-left
portal shunt (Rex shunt) has also been used for portal vein
thrombosis; it allows restoration of normal hepatopedal
flow (which results in fewer neurologic effects). This shunt
has been used to decompress portal hypertension in primary
portal vein thrombosis and in portal vein thrombosis that
has developed after liver transplant. The best outcomes
have been described in patients in whom the internal
jugular vein was used for the shunt [43].
Surgical shunts are usually reserved for treatment of
portal hypertension when transplant is not an option; in
patients with compensated cirrhosis in whom transplant is
unlikely to occur soon; and in patients with multiple
variceal bleeds that are refractory to both endoscopic and
medical management.
Conclusions
Management of portal hypertension in children focuses on
preventing and controlling variceal bleeding. Treatment in
children has evolved over the past several decades as more
studies have compared the efficacy of various medical,
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endoscopic, and surgical techniques in children. Although
the adult studies are important and are often the basis for
empiric therapy in children, the importance of randomized
controlled trials to test these techniques in children cannot
be overstated.
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